DXCM vs ABT Stock Comparison: AI Score, Valuation, Performance and Upside
DexCom and Abbott are the two global CGM market leaders competing for diabetes patients' glucose monitoring preference. DexCom has the most accurate and ecosystem-integrated CGM in the US market. Abbott's FreeStyle Libre has the highest global user count with lower prices and longer 14-day wear winning internationally. DexCom is a pure-play CGM investment; Abbott is a diversified healthcare company where CGM is one of four business segments.
DXCM vs ABT is the pure-play premium CGM accuracy and AID integration leader with G7 and Stelo (DexCom) versus the world's largest CGM user base through FreeStyle Libre combined with diversified medical devices, diagnostics, and nutrition businesses (Abbott) — pure-play CGM innovation vs diversified healthcare company with CGM leadership.
DXCM holds the edge across 3 of 5 key metrics in this comparison. DXCM has delivered stronger 1-year price return (+15.03% vs -23.81%), though ABT has the better forward P/E setup (16.81x vs 29.07x for DXCM). DXCM leads on both revenue growth (13.10%) and operating margin (24.33%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for ABT (+17.96%) than for DXCM (+3.63%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- prefer pure-play CGM exposure with maximum leverage to diabetes technology adoption growth without diversification dilution
- value DexCom's AID loop integration with insulin pumps creating ecosystem switching costs beyond sensor accuracy alone
- want the most innovative CGM platform with G7 accuracy leadership and Stelo OTC expanding the addressable market to Type 2 non-insulin users
- are comfortable with Abbott Libre competition on price and international market share, GLP-1 drug demand displacement risk, and premium pure-play valuation
- prefer diversified medical device and healthcare company with FreeStyle Libre CGM as the largest global user base alongside medical devices, diagnostics, and nutrition businesses
- value Abbott's Libre pricing advantage winning internationally where DexCom's premium price limits penetration
- want CGM exposure within a safer, more diversified healthcare holding with multiple segment growth drivers beyond diabetes technology
- are comfortable with less pure-play CGM upside per share and DexCom's accuracy advantage in AID systems
| Metric | DXCM | ABT |
|---|---|---|
| AI scorei | 52.1 | 50.3 |
| AI ranki | #414 | #528 |
| Latest closei | $87.93 | $102.23 |
| 1M returni | -1.86% | -9.27% |
| 6M returni | +30.71% | -4.63% |
| 1Y returni | +15.03% | -23.81% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | DXCM | ABT |
|---|---|---|
| 1Y ago | $11.6K (+16.0%) started 2025-09-18 | $7.6K (-24.0%) started 2025-09-18 |
| 5Y ago | $6.31K (-36.9%) started 2021-09-20 | $9.44K (-5.6%) started 2021-09-20 |
| 10Y ago | $37.79K (+277.9%) started 2016-09-19 | $34.28K (+242.8%) started 2016-09-19 |
Hypothetical — past performance does not guarantee future results.
| Metric | DXCM | ABT |
|---|---|---|
| Market capi | $34.27B | $176.41B |
| Trailing P/Ei | 35.90 | 32.99 |
| Forward P/Ei | 29.07 | 16.81 |
| Price/Salesi | 8.19 | 5.49 |
| EV/Revenuei | 6.79 | 4.38 |
| Analyst targeti | $94.12 | $120.26 |
| Target upsidei | +3.63% | +17.96% |
| Metric | DXCM | ABT |
|---|---|---|
| Revenue growthi | 13.10% | 13.00% |
| Earnings growthi | 43.60% | -47.50% |
| EPS growthi | +43.60% | -47.50% |
| FCF margini | +20.55% | +15.48% |
| Operating margini | 24.33% | 14.71% |
| Profit margini | 20.12% | 11.65% |
| ROIC proxyi | 38.49% | 10.58% |
| Return on equityi | 38.49% | 10.58% |
| Dividend yieldi | N/A | 2.47% |
| Payout ratioi | 0.00% | 78.96% |
| Dividend growth streaki | N/A | No increase yet |
| Betai | 1.41 | 0.59 |
| Debt/equityi | 53.35 | 63.21 |
| Current ratioi | 1.73 | 1.38 |
| Quick ratioi | 1.37 | 0.80 |
Over the past year, DXCM and ABT have moved weakly in the same direction (correlation of 0.26), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | DXCM | ABT |
|---|---|---|---|
| 1Y | Growthi | +16.03% | -24.03% |
| CAGRi | +16.05% | -24.05% | |
| Volatilityi | 41.18% | 26.76% | |
| Sharpe ratioi | 0.46 | -1.06 | |
| Sortino ratioi | 0.66 | -1.47 | |
| Max drawdowni | 27.63% | 39.57% | |
| Current drawdowni | 4.78% | 25.17% | |
| Avg drawdowni | 10.12% | 19.30% | |
| Ulcer Indexi | 11.99% | 22.22% | |
| Max daily dropi | 14.63% | 10.04% | |
| Max wkly dropi | 17.22% | 13.11% | |
| 5Y | Growthi | -36.94% | -12.20% |
| CAGRi | -8.82% | -2.57% | |
| Volatilityi | 47.32% | 23.04% | |
| Sharpe ratioi | -0.04 | -0.19 | |
| Sortino ratioi | -0.06 | -0.27 | |
| Max drawdowni | 66.32% | 40.85% | |
| Current drawdowni | 45.99% | 26.76% | |
| Avg drawdowni | 40.60% | 17.55% | |
| Ulcer Indexi | 43.57% | 19.81% | |
| Max daily dropi | 40.66% | 10.04% | |
| Max wkly dropi | 42.68% | 13.11% | |
| 10Y | Growthi | +277.95% | +188.10% |
| CAGRi | +14.23% | +11.17% | |
| Volatilityi | 48.74% | 24.01% | |
| Sharpe ratioi | 0.43 | 0.37 | |
| Sortino ratioi | 0.62 | 0.53 | |
| Max drawdowni | 66.32% | 40.85% | |
| Current drawdowni | 45.99% | 26.76% | |
| Avg drawdowni | 28.00% | 10.84% | |
| Ulcer Indexi | 33.86% | 14.55% | |
| Max daily dropi | 40.66% | 10.04% | |
| Max wkly dropi | 42.68% | 16.72% |
| Category | DXCM | ABT |
|---|---|---|
| Company | DexCom, Inc. | Abbott Laboratories |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Core business | DexCom is the market leader in continuous glucose monitoring (CGM) systems for people with diabetes, producing the G7 and Stelo CGM sensors that provide real-time glucose readings every 5 minutes without fingerstick testing. DexCom's CGM is used for both Type 1 and Type 2 diabetes management, and the Stelo product targets non-insulin-using Type 2 diabetics (a much larger population). Integration with insulin pumps (automated insulin delivery — AID) creates a compelling CGM-in-the-loop diabetes management system. | Abbott is a broad-line healthcare products company operating four segments: Medical Devices (including FreeStyle Libre CGM), Diagnostics (including Alinity analyzers), Established Pharmaceuticals (branded generics in emerging markets), and Nutrition (Ensure, Similac). Abbott's FreeStyle Libre CGM is the world's largest CGM platform by users globally — Libre's lower price and 14-day sensor wear have driven remarkable international adoption. Abbott is far more diversified than DexCom — CGM is only one of Abbott's four business lines. |
| Investor focus | Investors track new patient starts (the primary growth metric), Stelo OTC CGM penetration into the non-insulin Type 2 market, international expansion, and competitive pricing pressure from Abbott's FreeStyle Libre. | Investors track FreeStyle Libre CGM revenue growth, Medical Devices segment revenue, and Diagnostics recovery after COVID test demand normalization. |
- CGM market pioneer with the most established prescriber relationships — endocrinologists have prescribed DexCom for years, creating prescribing habits that persist
- G7 sensor is the most accurate CGM on the market — 10-day wear with factory calibrated accuracy that clinical studies show outperforms Abbott FreeStyle Libre 3 on some metrics
- Automated insulin delivery (AID) loop integration with Tandem, Insulet, and insulin pump makers creates ecosystem lock-in as patients build AID systems around DexCom's CGM
- FreeStyle Libre is the world's largest CGM platform — higher international penetration than DexCom with lower price and 14-day sensor wear addressing broader markets
- Abbott's diversification across medical devices, diagnostics, nutrition, and pharmaceuticals creates earnings stability through any single segment's cycle
- Libre's lower price point is winning in international and value-sensitive markets where DexCom's premium pricing has lower penetration
- Abbott FreeStyle Libre has become the global CGM market share leader by volume — Libre's lower price and 14-day sensor wear are winning in markets outside the US
- Stelo OTC launch into Type 2 non-insulin market faces channel and reimbursement challenges without established prescriber relationships in primary care
- GLP-1 drugs (Ozempic, Wegovy) may reduce CGM demand among Type 2 diabetics who achieve better glycemic control through weight loss on GLP-1 therapy
- Abbott's Libre faces GLP-1 drug demand impact on Type 2 CGM usage similar to DexCom's risk
- DexCom G7's clinical accuracy advantage may matter more as the AID market grows, where accuracy is critical for automated dosing decisions
- Abbott's diversification means CGM is not the only growth driver — investors wanting pure CGM exposure get less per Abbott share than per DexCom share
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.